Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mateon Therapeutics Inc (NASDAQ:MATN)

0.62
Delayed Data
As of Sep 30
 +0.01 / +1.64%
Today’s Change
0.49
Today|||52-Week Range
1.20
-18.41%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$16.2M

Company Description

Mateon Therapeutics, Inc. is a biopharmaceutical company, which focus on the development of vascular disrupting agents, or VDAs, for the treatment of cancer. It products include VDAs-CA4P and OXi4503. The company was founded in 1988 and is headquartered in South San Francisco, CA.

Contact Information

Mateon Therapeutics, Inc.
701 Gateway Boulevard
South San Francisco California 94080
P:(650) 635-7000
Investor Relations:

Employees

Shareholders

Other institutional5.14%
Mutual fund holders3.28%
Individual stakeholders--

Top Executives

William D. SchwietermanChairman, President & Chief Executive Officer
Matthew M. LoarChief Financial & Accounting Officer
David J. ChaplinChief Scientific Officer & Director
Kathleen M. LeeVice President-Chemistry, Manufacturing & Controls
Alice M. VargaVP-Regulatory Affairs & Quality Assurance